Terms: = Lymphoma AND SOCS1, O15524, 8651, ENSG00000185338, SOCS-1, SSI-1, SSI1, Cish1, JAB, CISH1, CIS1, TIP3
100 results:
1. Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics.
Cao B; Sun C; Bi R; Liu Z; Jia Y; Cui W; Sun M; Yu B; Li X; Zhou X
BMC Med Genomics; 2024 Apr; 17(1):84. PubMed ID: 38609996
[TBL] [Abstract] [Full Text] [Related]
2. Next Generation Sequencing Analysis of Fibrin-associated Large B-cell lymphoma Reveals Pathogenic Single Nucleotide Variants.
DO J; Yenwongfai LN; DO SI; Na K
Anticancer Res; 2024 Feb; 44(2):665-672. PubMed ID: 38307569
[TBL] [Abstract] [Full Text] [Related]
3. [CD23 positive, BCL2 rearrangement-negative germinal centre lymphomas].
Menter T; Quintanilla-Martinez L
Pathologie (Heidelb); 2023 Dec; 44(Suppl 3):160-163. PubMed ID: 37932478
[TBL] [Abstract] [Full Text] [Related]
4. Anaplastic Large Cell Transformation of Mycosis Fungoides: Case Report and Review of the Literature.
Flerova E; Alpdogan O; Bhatti S; Nikbakht N; Wang ZX; Gong JZ
Am J Dermatopathol; 2023 Sep; 45(9):e74-e82. PubMed ID: 37625813
[TBL] [Abstract] [Full Text] [Related]
5. Histone methyltransferase KMT2D inhibits ENKTL carcinogenesis by epigenetically activating SGK1 and socs1.
Zhang YH; Tao Q; Zhang WY; Zhao S; Liu WP; Gao LM
Genes Genomics; 2024 Feb; 46(2):203-212. PubMed ID: 37523130
[TBL] [Abstract] [Full Text] [Related]
6. Integrated genetic analyses of immunodeficiency-associated Epstein-Barr virus- (EBV) positive primary CNS lymphomas.
Kaulen LD; Denisova E; Hinz F; Hai L; Friedel D; Henegariu O; Hoffmann DC; Ito J; Kourtesakis A; Lehnert P; Doubrovinskaia S; Karschnia P; von Baumgarten L; Kessler T; Baehring JM; Brors B; Sahm F; Wick W
Acta Neuropathol; 2023 Sep; 146(3):499-514. PubMed ID: 37495858
[TBL] [Abstract] [Full Text] [Related]
7. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.
Russler-Germain DA; Krysiak K; Ramirez C; Mosior M; Watkins MP; Gomez F; Skidmore ZL; Trani L; Gao F; Geyer S; Cashen AF; Mehta-Shah N; Kahl BS; Bartlett NL; Alderuccio JP; Lossos IS; Ondrejka SL; Hsi ED; Martin P; Leonard JP; Griffith M; Griffith OL; Fehniger TA
Blood Adv; 2023 Sep; 7(18):5524-5539. PubMed ID: 37493986
[TBL] [Abstract] [Full Text] [Related]
8. Progression of Hodgkin lymphoma and plasma cell neoplasms: Report from the 2021 SH/EAHP Workshop.
Nejati R; Amador C; Czader M; Thacker E; Thakkar D; Dave SS; Dogan A; Duffield A; Goodlad JR; Ott G; Wasik MA; Xiao W; Cook JR
Am J Clin Pathol; 2023 Jun; 159(6):598-613. PubMed ID: 37085150
[TBL] [Abstract] [Full Text] [Related]
9. Deciphering the spectrum of cutaneous lymphomas expressing TFH markers.
Donzel M; Trecourt A; Balme B; Harou O; Mauduit C; Bachy E; Guesquières H; Fontaine J; Ortonne N; Perier-Muzet M; Dalle S; Traverse-Glehen A
Sci Rep; 2023 Apr; 13(1):6500. PubMed ID: 37081015
[TBL] [Abstract] [Full Text] [Related]
10. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
Shen R; Fu D; Dong L; Zhang MC; Shi Q; Shi ZY; Cheng S; Wang L; Xu PP; Zhao WL
Signal Transduct Target Ther; 2023 Apr; 8(1):145. PubMed ID: 37032379
[TBL] [Abstract] [Full Text] [Related]
11. [miR-155-5p alleviates lipopolysaccharide-induced inflammatory damage of human SH-SY5Y neuroblastoma cells by down-regulating socs1].
Zhou H; Zhou L; Zhang C; Zhou L; Han Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Mar; 39(3):220-229. PubMed ID: 36946346
[TBL] [Abstract] [Full Text] [Related]
12. Structural analysis and conformational dynamics of socs1 gene mutations involved in diffuse large B-cell lymphoma.
Dristy TT; Noor AR; Dey P; Saha A
Gene; 2023 May; 864():147293. PubMed ID: 36813059
[TBL] [Abstract] [Full Text] [Related]
13. Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study.
Michot JM; Quivoron C; Sarkozy C; Danu A; Lazarovici J; Saleh K; El-Dakdouki Y; Goldschmidt V; Bigenwald C; Dragani M; Bahleda R; Baldini C; Arfi-Rouche J; Martin-Romano P; Tselikas L; Gazzah A; Hollebecque A; Lacroix L; Ghez D; Vergé V; Marzac C; Cotteret S; Rahali W; Soria JC; Massard C; Bernard OA; Dartigues P; Camara-Clayette V; Ribrag V
Am J Hematol; 2023 Apr; 98(4):645-657. PubMed ID: 36606708
[TBL] [Abstract] [Full Text] [Related]
14. [Effect of HDAC Inhibitor Chidamide on PD-L1 Expression in Peripheral T-Cell lymphoma].
Yan MM; Li ZX; Chen C; Zhang W; Zhou DB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1741-1745. PubMed ID: 36476897
[TBL] [Abstract] [Full Text] [Related]
15. Transformation of FL into DLBCL with a PMBL gene expression signature.
Loveday T; Duns G; Rimsza LM; Rech KL; Cook JR; Robetorye RS; Rosenthal AC; Ramsower CA; Yip TK; McKinney CL; Swerdlow SH; Bhavsar S; Steidl C; Gibson SE
Blood Adv; 2023 Mar; 7(6):893-899. PubMed ID: 36240289
[TBL] [Abstract] [Full Text] [Related]
16. socs1 Gene Therapy for Head and Neck Cancers: An Experimental Study.
Kajiyama T; Serada S; Fujimoto M; Ohkawara T; Komori M; Hyodo M; Naka T
Anticancer Res; 2022 Jul; 42(7):3361-3372. PubMed ID: 35790291
[TBL] [Abstract] [Full Text] [Related]
17. Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell lymphomas.
Kim SJ; Kim YJ; Yoon SE; Ryu KJ; Park B; Park D; Cho D; Kim HY; Cho J; Ko YH; Park WY; Kim WS
Cancer Res Treat; 2023 Jan; 55(1):291-303. PubMed ID: 35240014
[TBL] [Abstract] [Full Text] [Related]
18. Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study.
Camus V; Viennot M; Lévêque E; Viailly PJ; Tonnelet D; Veresezan EL; Drieux F; Etancelin P; Dubois S; Stamatoullas A; Tilly H; Bohers E; Jardin F
Leuk Lymphoma; 2022 Apr; 63(4):834-844. PubMed ID: 35075971
[TBL] [Abstract] [Full Text] [Related]
19. Combination of two monoclonal antibodies with socs1 N- and C-terminal binding sites to address socs1 status in B cells and B-cell lymphoma.
Weissinger SE; Zahn M; Marienfeld R; Tessmer C; Moldenhauer G; Möller P
Eur J Haematol; 2022 Mar; 108(3):223-231. PubMed ID: 34854137
[TBL] [Abstract] [Full Text] [Related]
20. Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.
Balasubramanian S; Hodkinson B; Schuster SJ; Fowler NH; Trotman J; Hess G; Cheson BD; Schaffer M; Sun S; Deshpande S; Vermeulen J; Salles G; Gopal AK
Cancer Med; 2022 Jan; 11(1):61-73. PubMed ID: 34791836
[TBL] [Abstract] [Full Text] [Related]
[Next]
